Diferido
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
181,9 SEK | 0,00 % | +3,71 % | +36,05 % |
15/02 | El director financiero interino de Biotage pasa a ser permanente | MT |
15/02 | Transcript : Biotage AB, Q4 2023 Earnings Call, Feb 15, 2024 |
Resumen de negocios
Número de empleados: 674
Ventas por actividad
SEK en millones | 2021 | Peso | 2022 | Peso | Delta |
---|---|---|---|---|---|
Small Molecules and Synthetic Therapeutics
49,1
%
| - | - | 770 | 49,1 % | - |
Analytical Testing
24,4
%
| - | - | 382 | 24,4 % | - |
Scale-up
11,6
%
| 186 | 15,1 % | 181 | 11,6 % | -2,69 % |
Water and Environmental Testing
7,8
%
| - | - | 122 | 7,8 % | - |
Biologics and Advanced Therapeutics
4,2
%
| - | - | 66 | 4,2 % | - |
Diagnostics
2,9
%
| - | - | 46 | 2,9 % | - |
Ventas por región
SEK en millones | 2021 | Peso | 2022 | Peso | Delta |
---|---|---|---|---|---|
North and South America
42,1
%
| 481 | 39,1 % | 660 | 42,1 % | +37,21 % |
EMEA
24,0
%
| 343 | 27,9 % | 376 | 24,0 % | +9,62 % |
China
14,8
%
| 173 | 14,1 % | 232 | 14,8 % | +34,10 % |
Japan
7,3
%
| 111 | 9,0 % | 115 | 7,3 % | +3,60 % |
South Korea
3,9
%
| 52 | 4,2 % | 61 | 3,9 % | +17,31 % |
EMEA and APAC
3,6
%
| 27 | 2,2 % | 56 | 3,6 % | +107,41 % |
India
2,0
%
| 26 | 2,1 % | 32 | 2,0 % | +23,08 % |
Sweden
1,1
%
| 17 | 1,4 % | 18 | 1,1 % | +5,88 % |
Association of Southeast Asian Nations
1,0
%
| - | - | 16 | 1,0 % | - |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 72 | 09/02/06 | |
Andrew Kellett
DFI | Director of Finance/CFO | - | 25/09/23 |
Chief Tech/Sci/R&D Officer | 54 | - | |
Magnus Nordstedt
CTO | Chief Tech/Sci/R&D Officer | 54 | 01/01/02 |
Anders Wikström
COO | Chief Operating Officer | 51 | 01/10/02 |
Lisa Egelrud
LAW | General Counsel | 49 | - |
Sales & Marketing | 50 | - | |
Olof Nord
PRN | Corporate Officer/Principal | 49 | - |
Petra Duprez
HRO | Human Resources Officer | 59 | 01/05/20 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 72 | 09/02/06 | |
Åsa Hedin
BRD | Director/Board Member | 62 | 01/11/19 |
Kieran Murphy
CHM | Chairman | 61 | 04/01 |
Karolina Lawitz
BRD | Director/Board Member | 68 | 26/04/12 |
Director/Board Member | 69 | - | |
Mark Bradley
BRD | Director/Board Member | 62 | 24/04/19 |
Karen Sørensen
BRD | Director/Board Member | 62 | - |
Daniel Menasco
BRD | Director/Board Member | 47 | 01/01/15 |
Pär Lundgren
BRD | Director/Board Member | 39 | - |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 80 008 185 | 79 645 985 ( 99,55 %) | 0 | 99,55 % |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Biotage Sweden AB
Biotage Sweden AB Medical SpecialtiesHealth Technology Part of Biotage AB, Biotage Sweden AB is a Swedish impact tech company committed to solving society ’ s problems. The private company is based in Uppsala, Sweden. The company offers solutions in drug discovery, analytical, water, and environmental testing. Biotage provides workflow solutions and products to customers in drug discovery and development, analytical testing, and water and environmental testing. The company was founded in 1989 by Sheridan G. Snyder. |
Medical Specialties
|
Sector
Ventas por actividad
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+36,05 % | 1381,47 M | |
-33,47 % | 3226,16 M | |
+12,64 % | 1787,05 M | |
-0,43 % | 1674,69 M | |
-3,90 % | 1108,98 M | |
-20,26 % | 915 M | |
-6,26 % | 738 M | |
-11,90 % | 716 M | |
+12,74 % | 537 M | |
-.--% | 307 M |
- Bolsa
- Acciones
- Acción Biotage AB - Nasdaq Stockholm
- Empresa Biotage AB